A double blind placebo-controlled randomised trial of the addition of mirtazapine for patients with depression in primary care who have not responded to at least 6 weeks of treatment with a selective serotonin reuptake inhibitor or serotonin and noradrenaline reuptake inhibitor.

niversity of Bristol (UK)0 个研究点目标入组 400 人开始时间: 2012年9月20日最近更新: 2019年1月14日

适应症

试验速览

•1. Aged 18-75 years
•2. Currently taking any of the following SSRI or SNRI antidepressants, for at least 6 weeks at recommended (BNF) doses:
•2.1. Fluoxetine
•2.2. Sertraline
•2.3. Citalopram
•2.4. Escitalopram
•2.5. Fluvoxamine
•2.6. Paroxetine
•2.7. Duloxetine
•2.8. Venlafaxine and who have done so for at least 6 weeks at
•3. Patients who score 14 or more on the Beck Depression Inventory (BDI)
•4. Patients who have adhered to their medication and meet ICD-10 criteria for depression (assessed using the Computerised Interview Schedule ? Revised version (CIS-R))

•GPs will be asked to exclude patients who have bipolar disorder, psychosis or alcohol/substance abuse/dependence or who are pregnant. In addition, we will exclude patients who: are not able to complete the study questionnaires or have a past history of an adverse reaction to mirtazapine.

发起方

niversity of Bristol (UK)